🚀
Moderna and Merck have officially passed the Phase 3 trial for their cancer vaccine, proving it can effectively stop melanoma from returning. This study monitored 1,137 patients with high-risk skin cancer who had their tumors surgically removed.
Think of this not as a preventative vaccine like you get for the flu, but as a custom-made defense system. 🧬 After surgeons remove your tumor, they analyze its specific mutations to create a treatment based on mRNA—essentially a set of biological instruction codes—tailored just for your body. The goal is to train your immune system to recognize and attack any lingering cancer cells that might otherwise cause a relapse.
In this trial, the vaccine was used alongside Keytruda, an existing cancer drug. When compared to patients receiving only Keytruda, those who took the combination saw significantly better results in preventing the cancer from coming back or spreading. Following these results, Moderna saw its stock value climb by approximately 177%.
It’s a huge step forward in creating treatments that are uniquely designed for the individual. 🔥
The future of medicine is becoming deeply personal.
#Moderna #Merck #CancerResearch
Ars Technica
Subscribe
